Foscarnet Sodium has 16 known drug interactions based on U.S. FDA drug labeling data. 16 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acyclovir, Amiodarone, Amphotericin B. Patients taking Foscarnet Sodium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 16
- Major
- 16
Major (16)
- Foscarnet Sodium + Acyclovir— Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.
- Foscarnet Sodium + Amiodarone— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Amphotericin B— Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.
- Foscarnet Sodium + Cyclosporine— Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.
- Foscarnet Sodium + Dofetilide— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Foscavir— Drug Interactions A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described. Concomitant tr…
- Foscarnet Sodium + Loop Diuretics— May impair foscarnet elimination by inhibiting renal tubular secretion, potentially leading to toxicity. Thiazides recom…
- Foscarnet Sodium + Methotrexate— Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.
- Foscarnet Sodium + Pentamidine— Concomitant use may cause severe hypocalcemia and renal impairment; one patient death reported with severe hypocalcemia.
- Foscarnet Sodium + Phenothiazines— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Procainamide— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Quinidine— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Ritonavir— Abnormal renal function observed during concurrent use with foscarnet and ritonavir.
- Foscarnet Sodium + Saquinavir— Abnormal renal function observed during concurrent use with foscarnet, ritonavir, and saquinavir.
- Foscarnet Sodium + Sotalol— Should be avoided due to risk of QT prolongation and torsades de pointes.
- Foscarnet Sodium + Tacrolimus— Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.